Pharmaceutical composition for the treatment and/or prevention of degenerative retinal diseases (Machine-translation by Google Translate, not legally binding)

Pharmaceutical composition for the treatment and/or prevention of degenerative retinal diseases. The present invention relates to a composition comprising mesenchymal stem cells (mscs), preferably derived from adipose tissue (ad-mscs), combined with vasoactive intestinal peptide (vip) and nicotinami...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: FERNANDEZ BUENO, IVAN, SINGH, AMAR KUMAR, PASTOR JIMENO, JOSE CARLOS, GAYOSO RODRIGUEZ, MANUEL JOSE, SRIVASTAVA, GIRISH KUMAR
Format: Patent
Sprache:eng ; spa
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pharmaceutical composition for the treatment and/or prevention of degenerative retinal diseases. The present invention relates to a composition comprising mesenchymal stem cells (mscs), preferably derived from adipose tissue (ad-mscs), combined with vasoactive intestinal peptide (vip) and nicotinamide (nic), and more preferably also combined with retinoic acid (atra) and with supernatant of a retinal pigment epithelial cell culture (epr). It also relates to the use of this composition for the treatment and/or prevention of retinal damage, preferably degenerative diseases of the retina, for example, but without limitation, degenerative diseases of rpe, photoreceptors and neuroretina. (Machine-translation by Google Translate, not legally binding) Composición farmacéutica para el tratamiento y/o prevención de enfermedades retinianas degenerativas. La presente invención se refiere a una composición que comprende células madre mesenquimales (MSCs), preferiblemente procedentes de tejido adiposo (AD-MSCs), combinadas con péptido intestinal vasoactivo (VIP) y nicotinamida (NIC), y más preferiblemente combinadas además con ácido retinoico (ATRA) y con sobrenadante de un cultivo de células del epitelio pigmentario de la retina (EPR). También se refiere al uso de esta composición para el tratamiento y/o prevención de daños retinianos, preferiblemente de enfermedades degenerativas de la retina, por ejemplo, aunque sin limitarnos, enfermedades degenerativas del EPR, de los fotorreceptores y de la neurorretina.